By steadily pumping money into these three stocks, you may be on your way to retiring with a million dollars or more.
Apple's (NASDAQ: AAPL) stock price climbed 3.2% on Tuesday, despite a sharp fall in the major market indices. Investors were startled by comments from Federal Reserve Chair Jerome Powell, which suggested that the powerful central bank could pull back on stimulus measures sooner than it forecasted. Many analysts had expected the Fed to adopt a more supportive stance toward the economy after health officials detected a worrisome new coronavirus strain that threatens to derail the market's recovery.
Investors are rattled by the FDA's request for an out-of-the-ordinary meeting dedicated to scrutinizing the company's latest drug approval request.
Wall Street has known its share of legends, but few of them have made as big a splash as “the Man Who Broke the Bank of England.” That nickname belongs to George Soros who earned the tag after famously betting against the British Pound in 1992; following the Black Wednesday crash, the hedge fund manager pocketed $1 billion in a single day. This is the stuff that Wall Street legends are made of. By then Soros was already incredibly successful and in the midst of steering his Quantum Fund to decad
Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.
Satya Nadella sold 838,584 shares between Nov. 23 and Nov. 24. The move comes a month before Washington state's capital gains tax goes into effect.
Multiple factors are making investors in the EV stock very jittery.
On Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). With the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. Billionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions.
On yet more worrying news about the omicron variant of the coronavirus, the fortunes of coronavirus stocks were mixed on Tuesday. In contrast the co-developer of Pfizer's jab, BioNTech (NASDAQ: BNTX), was down by almost 3%. It's interesting that the fortunes of partners Pfizer and BioNTech, which together developed the Comirnaty vaccine, were diverging so sharply.
The shares were one of the few bright spots as markets sold off sharply, with almost every other major tech stock trading in the red.
Fed Chair Powell and Treasury Secretary Yellen give their testimonies to the Senate Banking Committee on the outlook for inflation.
As I was extolling the virtues of Social Security’s 5.9% COLA, the Centers for Medicare and Medicaid Services (CMS) announced that they were increasing the premium for Medicare Part B by 14.5%. As a reminder, Medicare is composed of two programs. Part A, Hospital Insurance (HI), which covers inpatient hospital services, skilled nursing facilities, home healthcare, and hospice care.
You only have a couple more days to profit in two different ways from tax-loss selling. From a statistical point of view, that means you’re finding a security whose gyrations can explain or predict at least half of the movements of your tax loss sale candidate.
Andrew Slimmon, Morgan Stanley Investment Management Managing Director and Sr. Portfolio Manager, joins Yahoo Finance to make sense of Tuesday's sell-off and preivew what to expect from the markets in 2022.
The prospect of shareholder dilution is a gray cloud looming on the horizon for this solar industry company.
Yahoo Finance Live's Julie Hyman breaks down some of the leading national headlines including Microsoft CED Satya Nadella selling half his stake in the company, Amazon allowing a new unionization vote in Alabama, and Lululemon firing back at Peloton with patent infringement lawsuit.
Bret Taylor, who has been president and chief operating officer, was promoted to co-CEO with Marc Benioff.
Shares of uranium mining companies Denison Mines (NYSEMKT: DNN), Energy Fuels (NYSEMKT: UUUU), and Uranium Energy (NYSEMKT: UEC) all crashed in Tuesday trading, falling 7%, 8.6%, and a disheartening 11.9%, respectively, through 1:25 p.m. ET. Since hitting its recent high of roughly $48 a pound on Nov. 15, uranium prices have twice more tried to break that barrier and resume their march toward $60 -- and twice failed, according to data from TradingEconomics.com. Today, uranium prices sit at just $47.25 a pound, which, granted, is about 50% higher than their lows of mid-August, but also still a far way away from $60.
Shares of Apple (NASDAQ: AAPL) stock closed up 2.2% on Monday following a holiday weekend that featured new commentary on the company and its products from Bloomberg. Last week, if you recall, Apple shares got a boost from reports that the company is planning to build an electric car with autonomous driving capability and also has an augmented reality headset in the works -- one that will be powerful enough to work as a stand-alone device. Well, over the weekend, Bloomberg expanded on these reports, adding that Apple is also working to develop augmented reality (AR) glasses (i.e., something different from the headset) and predicting that consumers (and investors) might get their first look at the AR headset as early as June 2022 if the company decides to unveil it at Apple's planned Worldwide Developers Conference next June.
Shares of ImmunoGen (NASDAQ: IMGN) surged 30% on Tuesday after the biotech announced promising clinical trial results for its experimental ovarian cancer therapy, mirvetuximab. The trial was designed to assess the safety and efficacy of mirvetuximab in patients with a form of platinum-resistant ovarian cancer who were already treated with Avastin (bevacizumab), a leading therapy developed by Roche-owned Genentech. "Despite advances in the platinum-sensitive setting, most patients with ovarian cancer eventually develop platinum-resistant disease, for which there are limited treatment options, especially for those patients who have previously received bevacizumab," co-principal investigator Robert Coleman said in a press release.
The professor is known for being bullish on stocks, yet even he says trouble’s coming.